As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

The Perrigo launch of their FDA approved OTC Opill is great news for women in the U.S. who rely on progesterone-only birth control pills for their contraception. Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

"I'm very pleased that the FDA has approved the sale of Opill OTC. However, it's crucial for women to recognize that this is not the same birth control pill familiar to them or their mothers," notes Mary Jane Minkin, M.D., an OBGYN and clinical professor at the Yale University School of Medicine. "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months. The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason. The progesterone only pill MUST be taken at the same time every single day within a 3-hour window. If you are over 3 hours late for the Opill, you should take it right away; but you need to use a condom for the next 48 hours, as it takes 2 days for the product to start working again. Nonetheless, the introduction of an OTC birth control pill is a positive step forward in expanding OTC contraceptive options for women in that they are more effective than condoms. It's vital that women are fully informed about these differences.”

For women over 35 who smoke or have a history of, or are at risk for, certain health conditions such as blood clots, stroke, and heart attacks, consulting with a healthcare practitioner is crucial to select the most suitable contraceptive method. The combination pill, known as "the Pill," is generally not recommended for this demographic due to the increased risk of cardiovascular problems. Additionally, those with conditions like uncontrolled high blood pressure, certain cancers (e.g., breast cancer), or migraines with aura should consider alternatives to estrogen-containing pills to avoid potential health complications. The Opill, or progesterone-only pill, represents a safer choice for individuals with these concerns, including women with diabetes without complications or those who are breastfeeding. Now available over the counter (OTC), the Opill offers a viable, less risky contraceptive option, underscoring the importance of personalized medical advice in choosing the right birth control.

“Given the variety of contraceptive methods available and personal health considerations, women can choose between combined pills, progesterone-only pills, and other forms of contraception based on their individual needs, preferences, and medical advice,” adds Minkin. “What great news this is for women and just the beginning of the journey towards reproductive access. The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.' New technologies are in the works as well. Another company has been working with the FDA for the past seven years to make their combination estrogen and progesterone birth control pill called Zena available OTC, eliminating the need for a prescription.”

In 1960, Enovid made history as the first birth control pill approved by the U.S. FDA, marking a revolution in reproductive health with its effective combination of estrogen and progesterone. This breakthrough not only provided women with a reliable form of contraception but also empowered them with greater control over their fertility and significantly reduced unintended pregnancies. Since then, oral contraceptives have evolved remarkably, with today's versions containing less than a third of the estrogen and progestin levels found in the original pills. This advancement has maintained the effectiveness of birth control while greatly enhancing safety, highlighting the progress in creating safer yet equally effective estrogen and progestin-based contraceptives.

"In light of the FDA's recent over-the-counter approval of the Opill, a progesterone-only contraceptive, we stand at a pivotal moment in expanding access to reproductive choices for women," adds Minkin. "This advancement paves the way for millions of women to use oral contraception without the need for a prescription safely and opens the door to making the combined hormonal birth control pill available without a prescription as well."

With the introduction of the Opill, alongside efforts to increase accessibility to OTC-approved emergency contraceptives in underserved areas and contraceptive deserts, we are making significant strides toward empowering women with more control over their reproductive health. This marks the beginning of a new era in contraceptive options, promising enhanced safety, accessibility, and autonomy for women across the United States, making it possible for millions of young women without health insurance to have access to oral contraception.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240311050991/en/